BioQ Pharma Enters into Strategic Partnership with Galen Limited to Commercialize Three Ready-to-Use Infusion Products in the United Kingdom and Ireland

SAN FRANCISCO, Dec. 06, 2016 -- BioQ Pharma Incorporated, a specialty pharmaceutical company, today announced the signing of a strategic distribution, supply and development agreement to commercialize three infusion pharmaceuticals in the United Kingdom and the Republic of Ireland with Galen Limited, a specialty pharmaceutical company marketing products within the UK, Ireland, Europe and the US in therapeutic areas such as pain management, gastroenterology and female health.

"We are delighted to partner with Galen Limited.  Galen has a distinguished history in commercializing pharmaceutical products internationally. Their experience in launching innovative combination products into hospitals in the UK and Ireland will be invaluable to our collective commercial efforts moving forward,” said Josh Kriesel, President and CEO of BioQ Pharma.

About BioQ Pharma
BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's commercial collaborators and strategic partners include Novartis' Sandoz unit, Cipla, Lee's Pharm, Lunatus, Galen Limited, and West Pharmaceutical Services.

Company Contact Information:

Josh Kriesel
President and CEO
415-336-6496

Ron Pauli
Chief Financial Officer
415-889-7707

Walter Cleymans
Vice President Europe
Phone: +32 474 (053) 253

Media:
Stephanie Carrington
Integrated Corporate Relations, Inc. (ICR)
646-277-1282